Stockscreener 앱 받기
8.39
2.63%
0.215
시간 외 거래:
8.39
전일 마감가:
$8.175
열려 있는:
$8.18
하루 거래량:
638.25K
Relative Volume:
0.88
시가총액:
$436.02M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-2.5579
EPS:
-3.28
순현금흐름:
$-78.56M
1주 성능:
+2.32%
1개월 성능:
-15.85%
6개월 성능:
-68.20%
1년 성능:
-27.67%
1일 변동 폭
$8.03
$8.44
1주일 범위
$7.975
$8.44
52주 변동 폭
$7.90
$36.25
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com
We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely - Yahoo Finance
Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 13.2% in October - MarketBeat
Assenagon Asset Management S.A. Has $16.68 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations - StockTitan
nVerses Capital LLC Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
4D Molecular Therapeutics stock hits 52-week low at $8.52 By Investing.com - Investing.com Australia
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics stock hits 52-week low at $8.52 - Investing.com India
Gene therapy for managing neovascular macular degeneration - Ophthalmology Times Europe
Recent Insider Activity Suggests Potential Gains for 4D Molecular Therapeutics Inc (FDMT) - Knox Daily
4D Molecular Therapeutics Inc (FDMT)’s Day in Review: Closing at 9.17, Up by 5.04 - The Dwinnex
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - Yahoo Finance
Prospect Capital Corp [PSEC] Investment Guide: What You Need to Know - Knox Daily
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is A Good Option To Consider - Stocks Register
Looking For A Top Momentum Stock? Check Out Service Properties Trust (NASDAQ: SVC) - Stocks Register
Metrics That Matter About Roper Technologies Inc (NASDAQ: ROP) - Stocks Register
FTAI Infrastructure Inc (NASDAQ: FIP) Is A Blank Check For Growth - Stocks Register
This trade activity should not be overlooked: 4D Molecular Therapeutics Inc (FDMT) - SETE News
4D Molecular Therapeutics Inc (FDMT)’s stock decline to 9.26 per share - US Post News
4D Molecular Therapeutics Inc (FDMT) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -3.58, Closing at 9.97 - The Dwinnex
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics Inc (FDMT) to a Neutral from an Overweight - Knox Daily
Dimensional Fund Advisors LP Sells 216,250 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 3.8%What's Next? - MarketBeat
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy FailureI'm Not So Sure - Seeking Alpha
4D Molecular Therapeutics, Inc. Is Being Investigated For Possib - WICZ
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Squarepoint Ops LLC - MarketBeat
Marshall Wace LLP Trims Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
4D-710 gene therapy helps overcome lack of response to CFTR modulators - BioWorld Online
Take off with 4D Molecular Therapeutics Inc (FDMT): Get ready for trading - SETE News
Investor’s Toolkit: Key Ratios for Assessing 4D Molecular Therapeutics Inc (FDMT)’s Performance - The Dwinnex
4D Molecular Therapeutics' SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com Australia
Profund Advisors LLC Decreases Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics Inc [FDMT] Investment Appeal on the Rise - Knox Daily
4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Top investors say 4D Molecular Therapeutics Inc (FDMT) ticks everything they need - SETE News
4D Molecular Therapeutics, Inc. Expected to Post FY2024 Earnings of ($2.68) Per Share (NASDAQ:FDMT) - MarketBeat
Did 4D Molecular Therapeutics Inc (FDMT) perform well in the last session? - US Post News
Closing Figures: 4D Molecular Therapeutics Inc (FDMT)’s Negative Finish at 11.61, Down -2.44 - The Dwinnex
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $11.90 - MarketBeat
Cantor Fitzgerald Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) to Neutral - MarketBeat
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference - Yahoo Finance
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 14.4% - Defense World
Rhumbline Advisers Has $1.53 Million Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Ratios Uncovered: Breaking Down 4D Molecular Therapeutics Inc (FDMT)’s Trailing Twelve Months Metrics - The Dwinnex
4D Molecular Therapeutics Inc [FDMT] Records 200-Day SMA of $22.26 - Knox Daily
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):